Among them, 110 (77.5%) had T1DM, and the rest had T2DM and used basal-and-bolus insulin as their primary treatment because of unsatisfied diabetic control with other hypoglycemic medications. This evidence concerns the gene INS and type 2 diabetes mellitus.